Abstract
As intracerebral hemorrahge becomes more frequent as a result of an aging population with greater comorbidities, rapid identification and reversal of precipitators becomes increasingly paramount. The aformentioned population will ever more likely be on some form of anticoagulant therapy. Understanding the mechanisms of these agents and means by which to reverse them early on is critical in managing the acute intracerebral hemorrhage.
Keywords:
anticoagulation; cerebral hemorrhage; coagulopathy reversal; hemorrhagic stroke.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Anticoagulants / adverse effects*
-
Blood Coagulation / drug effects*
-
Blood Coagulation Factors / therapeutic use
-
Cerebral Hemorrhage / blood
-
Cerebral Hemorrhage / chemically induced
-
Cerebral Hemorrhage / therapy*
-
Coagulants / adverse effects
-
Coagulants / therapeutic use*
-
Factor VIIa / therapeutic use
-
Factor Xa / therapeutic use
-
Factor Xa Inhibitors / adverse effects*
-
Humans
-
Plasma*
-
Recombinant Proteins / therapeutic use
-
Treatment Outcome
-
Vitamin K / antagonists & inhibitors
-
Vitamin K / therapeutic use
-
Warfarin / adverse effects*
Substances
-
Antibodies, Monoclonal, Humanized
-
Anticoagulants
-
Blood Coagulation Factors
-
Coagulants
-
Factor Xa Inhibitors
-
PRT064445
-
Recombinant Proteins
-
Vitamin K
-
prothrombin complex concentrates
-
Warfarin
-
idarucizumab
-
Factor VIIa
-
Factor Xa